PDL BIOPHARMA, INC. - 69329Y104
Detailed investor-level table based on 13F positions.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diversified Trust Co | History | Added to | 11,554 | 27 | 0.0% | 0.0% | 1 | +525 | 4.76% | Q1 2026 | Apr 16, 2026 |
| RHUMBLINE ADVISERS | History | No change | 612 | 1 | 0.0% | 0.0% | 2 | 0 | 0.0% | Q1 2026 | May 12, 2026 |
| HANCOCK WHITNEY CORP | History | Closed out | 0 | 0 | — | — | — | -128,394 | -100.0% | Q1 2026 | May 15, 2026 |
| Westside Investment Management, Inc. | History | No change | 500 | 0 | — | — | — | 0 | 0.0% | Q1 2026 | May 04, 2026 |
| Argent Trust Co | History | No change | 41,405 | 0 | — | — | — | 0 | 0.0% | Q1 2026 | May 13, 2026 |
| Financial Gravity Asset Management, Inc. | History | No change | 33 | 0 | — | — | — | 0 | 0.0% | Q1 2026 | May 08, 2026 |
| Motiv8 Investments LLC | History | No change | 875 | 0 | — | — | — | 0 | 0.0% | Q4 2025 | Feb 13, 2026 |
| Murphy & Mullick Capital Management Corp | History | No change | 100 | 0 | — | — | — | 0 | 0.0% | Q1 2026 | Apr 17, 2026 |